anti-CD19 CAR NK-cell therapy (Evotec/Institut Universitaire du Cancer de Toulouse Oncopole)

N/A

Report date: 2025/01/26 18:10:05

Base Information

Drug Nameanti-CD19 CAR NK-cell therapy (Evotec/Institut Universitaire du Cancer de Toulouse Oncopole)
Drug Alias Nameallogeneic iPSC-derived CAR iNK-cells (Evotec/Institut Universitaire du Cancer de Toulouse Oncopole)anti-CD19 CAR iNK-cell therapy (Evotec/Institut Universitaire du Cancer de Toulouse Oncopole)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEvotec SE
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Institute Cancer Toulouse OncopoleEvotec SE
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A